Mr. Miguel Martin reports

AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.

Aurora Cannabis Inc. has confirmed that Curaleaf Holdings Inc. has commenced an unsolicited takeover bid for all of the issued and outstanding common shares of the company at a stated implied consideration of $4 (U.S.) per Aurora share, consisting of 0.3463 subordinate voting share of Curaleaf plus 75 U.S. cents in cash per Aurora share. Aurora notes that the offer includes a cap on the value of the consideration of $5 (U.S.) per Aurora share, which is a lower price than Aurora shares have traded as recently as Dec. 18, 2025.

Miguel Martin, executive chairman and chief executive officer of Aurora, stated: "The strong shareholder support demonstrated at our 2026 AGM [annual general meeting] reinforces our commitment to the long-term strategy we are executing. We believe Curaleaf made a strategic decision to make its offer public to pressure our shareholders into making a short-term decision for the benefit of Curaleaf shareholders. We will not do that. We are building this company for the long term and will always do what is right for Aurora shareholders."

"Contrary to assertions by Curaleaf, our door is always open to those that see value in our company. Aurora has been in dialogue with Curaleaf going back to June 22, 2026, and as recently as Aug. 12, 2026. Their objective is to acquire Aurora's highly strategic EU-GMP [European Union good manufacturing practice] facilities and leading medical cannabis platforms at the lowest price possible, thereby depriving Aurora shareholders of any current and future value they generate," concluded Mr. Martin.

The offer follows an announcement by Curaleaf on Aug. 11, 2026, of its intention to make an offer for Aurora. At that time, Aurora confirmed that it received letters from Curaleaf dated June 23, 2026, and July 7, 2026, outlining proposals to acquire the Aurora shares. The June 23, 2026, letter contained no proposed financial terms and the July 7, 2026, letter included no detail regarding the mix of cash and share consideration being proposed by Curaleaf.

The company expects to provide a more comprehensive response to Aurora shareholders in a timely manner.

Take no action on offer

Aurora shareholders are advised to take no action on the offer until the board of directors of Aurora has made a formal recommendation to shareholders. The offer will remain open for a minimum of 105 days, allowing Aurora shareholders until at least Dec. 1, 2026, to consider their options.

The board has formed a special committee of independent directors. The special committee will consider the offer with its advisers before making a recommendation to the board. Aurora shareholders will be notified of the board's formal recommendation through a news release and director circular within 15 days, in accordance with applicable securities laws.

Advisers

Aurora has retained the following leading industry advisers:

• Legal counsel to Aurora's special committee is Torys LLP.
• Legal counsel to the company are Stikeman Elliott LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP.
• Fort Capital Partners is the company's financial adviser and ICR is the company's communications counsel.
• Kingsdale Advisors is the company's strategic adviser and information agent.

Shareholder assistance

Aurora shareholders with questions about the offer or who would like to stay informed may contact Kingsdale Advisors, the company's strategic advisor and information agent.

Toll-free (within North America):  1-800-749-9052

Call or text:  416-623-4172

E-mail:  contactus@kingsdaleadvisors.com

Shareholders should take no action at this time. Shareholders should wait until the board has provided its formal recommendation regarding the offer.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands, including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

We seek Safe Harbor.